Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer

International Journal of Cancer

Volumn 134, Issue 10, 2014, Pages 2284-2293

  Friedlander, Terence W ^a   Ngo, Vy T ^a   Dong, Huan ^b   Premasekharan, Gayatri ^a   Weinberg, Vivian ^a   Doty, Shaun ^a   Zhao, Qiang ^b   Gilbert, Elizabeth G ^a   Ryan, Charles J ^a   Chen, Wen Tien ^b   Paris, Pamela L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

circulating tumor cells; epithelial to mesenchymal transition; prostate cancer

Indexed keywords

CD45 ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; VIMENTIN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CELL ADHESION ASSAY; CELL INVASION; CELL ISOLATION; CELL LINEAGE; CELL POPULATION; CELL TRANSFORMATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COMPARATIVE STUDY; DNA METHYLATION; EPIGENETICS; EPITHELIUM CELL; FEASIBILITY STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INVASIVE CARCINOMA; MALE; MESENCHYME CELL; METASTASIS POTENTIAL; PRIORITY JOURNAL; STEM CELL;

CIRCULATING TUMOR CELLS; EPITHELIAL TO MESENCHYMAL TRANSITION; PROSTATE CANCER;

ANTIGENS, CD44; ANTIGENS, CD45; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CELL COUNT; CELL LINE, TUMOR; DNA METHYLATION; FLOW CYTOMETRY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84895920368     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28561     Document Type: Article

References (35)

1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005.
2. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-22.
3. Mukherji D, Pezaro CJ, De-Bono JS,. MDV3100 for the treatment of prostate cancer. Exp Opin Investig Drugs 2012; 21: 227-33.
4. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
5. De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9.
6. Mego M, Mani SA, Lee BN, et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int J Cancer 130: 808-16.
7. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-904.
8. Lu J, Fan T, Zhao Q, et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 126: 669-83.
9. Paris PL, Kobayashi Y, Zhao Q, et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett 2009; 277: 164-73.
10. Fan T, Zhao Q, Chen JJ, et al. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 2009; 112: 185-91.
11. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59.
12. Thomas PD, Kejariwal A, Campbell MJ, et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003; 31: 334-41.
13. Mi H, Dong Q, Muruganujan A, et al. PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res 38: D204-10.
14. Panther Classification System [database on the Internet] Los Angeles (CA): The University of Southern California. c2010-[cited October 7th Afhw.
15. Friedlander TW, Roy R, Tomlins SA, et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 72: 616-25.
16. Bibikova M, Le J, Barnes M, et al. Genome-wide DNA methylation profiling using Infinium assay. Epigenomics 2009; 1: 177-200.
17. Wright GL, Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-34.
18. Kawakami M, Nakayama J,. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997; 57: 2321-4.
19. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256-61.
20. Sokoloff RL, Norton KC, Gasior CL, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000; 43: 150-7.
21. Brandt B, Junker R, Griwatz C, et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res 1996; 56: 4556-61.
22. Molnar B, Ladanyi A, Tanko L, et al. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001; 7: 4080-5.
23. Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009; 15: 2091-7.
24. Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006; 12: 5615-21.
25. Tang DG, Patrawala L, Calhoun T, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007; 46: 1-14.
26. Liu AY, True LD, LaTray L, et al. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A 1997; 94: 10705-10.
27. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 29: 1547-55.
28. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-19.
29. Ghersi G, Zhao Q, Salamone M, et al. The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res 2006; 66: 4652-61.
30. Chen D, Kennedy A, Wang JY, et al. Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res 2006; 66: 9977-85.
31. Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13: 1736-41.
32. Kennedy A, Dong H, Chen D, Chen WT,. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer 2009; 124: 27-35.
33. Tanaka TS, Kunath T, Kimber WL, et al. Gene expression profiling of embryo-derived stem cells reveals candidate genes associated with pluripotency and lineage specificity. Genome Res 2002; 12: 1921-8.
34. Zhao Y, Yan Q, Long X, et al. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 2008; 26: 571-7.
35. Sun Y, Wang BE, Leong KG, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 72: 527-36.